Kidney Cancer

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.

“These data support the development of fianlimab plus cemiplimab combination therapy for patients with metastatic ccRCC,” said Miso Kim, MD, PhD.

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.

Various immunotherapy/TKI regimens were observed to determine the impact on survival in patients with metastatic renal cell carcinoma.

Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.

Data from CheckMate 214 show a steady improvement in overall survival with nivolumab/ipilimumab in patients with favorable-risk disease.

Developers designed ADI-270 to potentially improve clinical responses in patients with renal cell carcinoma and other CD70-positive tumors.

A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.

“Our analysis showed that the time to progression was later with the use of lenvatinib and pembrolizumab compared with sunitinib,” said Viktor Grünwald, MD, PhD.

Using the TILs CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative as predictive biomarkers did not impact outcomes in metastatic clear cell renal cell carcinoma.

Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.

Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.

Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.

Clinicians are learning how to identify adverse effects relating to either immunotherapy or tyrosine kinase inhibitors for patients with advanced renal cell carcinoma.

Moshe Ornstein, MD, discusses the heterogeneous population that comprise patients with advanced renal cell carcinoma.

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.